Serum chemerin is elevated in patients with metabolic syndrome complicated by degenerative aortic valve disease
10.3969/j.issn.1673-4254.2014.05.11
- VernacularTitle:代谢综合征合并主动脉瓣退行性病变患者血浆中的chemerin升高
- Author:
Ming DONG
1
;
Ting XIE
;
Xinzhong CHEN
;
Xuan CHEN
Author Information
1. 海南省人民医院心脏外科
- Keywords:
degenerative aortic valve disease;
metabolic syndrome;
adipokines;
chemerin
- From:
Journal of Southern Medical University
2014;(5):651-654
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the association of serum chemerin with degenerative aortic valve disease (DAVD) in patients with metabolic syndrome. Methods From July, 2012 to July, 2013, 48 patients with metabolic syndrome (mean age 56.33±6.14 years, including 25 male and 23 female patients), 48 patients with metabolic syndrome and DAVD (mean age 60.16± 6.72 years, 24 males and 21 females), and 48 adult healthy volunteers (mean age 52.94 ± 8.28 years, 23 males and 25 females) were examined for triglyceride, total cholesterol, low-density lipoprotein-cholesterol, high-density lipoprotein, fasting glucose, C-reactive protein and other biochemical indexes. Serum chemerin levels were detected using ELISA for all the subjects. Results Patients with metabolic syndrome had higher levels of serum chemerin than the healthy subjects, and patients with DAVD had higher chemerin levels than those with DAVD. Multivariate logistic regression analysis showed that increased serum chemerin level is a predictor of aortic valve degeneration in patients with metabolic syndrome. Univariate linear regression analysis showed that serum chemerin levels, body mass index, systolic blood pressure, total triglyceride and C-reactive protein were associated with metabolic syndrome. Stepwise multiple linear regression analysis identified correlations of body mass index and C-reactive protein with serum chemerin level. Conclusion Elevated serum chemerin level can be a predictor for DAVD in patients with metabolic syndrome.
